- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Results have been reported for a randomized clinical trial assessing the use of adjuvant chemotherapy for colon cancer in patients with circulating tumour DNA (ctDNA) post-surgery.
Post-surgery ctDNA predicts low recurrence-free survival. Patients with stage II colon cancer were assigned to either management guided by presence of ctDNA 4 or 7 weeks after surgery (n =
302), initiating a chemotherapy regimen, or standard management (n = 153). Two-year recurrence-free survival (the primary end point) for ctDNA-guided management was noninferior to standard
management (93.5% and 92.4%, respectively), and the ctDNA-guided approach reduced use of adjuvant chemotherapy.
Anyone you share the following link with will be able to read this content:
